AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026270322
Cite this article
1
Download
66
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

An exploratory PET/MR radiomics framework for preoperative prediction of HER2 status and metastatic burden in colorectal cancer

Zengbei Yuan1,2,3† ,  Kun Wang1,2† ,  Wen Jiang1,2† ,  Zhixian Tang1 ,  Xing Chen2 ,  Weilun Wang2 ,  Yihong Yang2 ,  Zirong Zhou2 ,  Jun Zhao2 ,  Qingqing Huang1* ,  Na Qi1,2*
Show Less
1 Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai , China
2 Department of Nuclear Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai , China
3 School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, Fujian , China
†These authors contributed equally to this work.
Received: 30 June 2026 | Revised: 12 September 2026 | Accepted: 28 October 2026 | Published online: 16 November 2026
(This article belongs to the Special Issue Deep Learning in Medical Image Analysis)
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Introduction: Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) status and metastatic burden in colorectal cancer remains challenging. Multimodal positron emission tomography (PET)/magnetic resonance (MR) radiomics offers an opportunity for integrated molecular and metastatic characterization.

Objective: To develop and internally validate an exploratory PET/MR radiomics framework for the preoperative prediction of HER2 status and metastatic burden (non-regional lymph nodes) in colorectal cancer (CRC) patients.

Methods: This retrospective study incorporated 61 samples with pathologically confirmed CRC who underwent preoperative 18F-fluorodeoxyglucose PET/MR imaging. HER2 positivity was defined according to the refined HER2 Amplification for CRC Enhanced Stratification criteria. Metastatic burden was categorized into three groups based on preoperative imaging: non-metastatic, regional lymph node metastasis, and distant metastasis. Tumor regions were manually segmented on PET, T1- and T2-weighted imaging (T1WI, T2WI), and 2,264 radiomic features were extracted from each imaging modality. Feature selection was performed using a comprehensive multi-step pipeline. An extreme gradient boosting (XGBoost)-based model was then developed and internally validated via 5-fold cross-validation, with performance metrics reported as mean ± standard deviation.

Results: For HER2 status prediction, the multimodal combined XGBoost model demonstrated superior performance compared to single-modality models, yielding a mean AUC of 0.9214 ± 0.0779. For metastatic burden prediction, the combined model further excelled, yielding an AUC of 0.827 ± 0.136. SHapley Additive exPlanations analysis revealed imaging signatures for the two prediction tasks. HER2 status prediction was primarily driven by texture-related features, particularly those derived from the Gray-Level Run Length Matrix, Gray-Level Co-occurrence Matrix, and First-order matrices, whereas metastatic burden prediction relied mainly on multiscale texture descriptors from the first-order, Neighborhood Gray-Tone Difference Matrix, and Gray-Level Dependence Matrix.

Conclusion: PET/MR radiomics offers an exploratory approach for future risk stratification in CRC, although independent validation is required to confirm clinical utility.

Keywords
Colorectal cancer
Machine learning
Positron emission tomography/magnetic resonance
Radiomics
SHapley Additive exPlanations
Funding
This work was supported by the construction project of the Shanghai Key Laboratory of Molecular Imaging (18DZ2260400).
Conflict of interest
The authors declare no conflict of interest.
References
  1. Chen N, He L, Zou Q, Deng H. HER2 targeted therapy in colorectal Cancer: Current landscape and future directions. Biochem Pharmacol. 2024;223:116101. doi: 10.1016/j.bcp.2024.116101
  2. Zhang R, Su C, Jia Y, Xing M, Jin S, Zong H. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer. Biomed Pharmacother. 2024;179:117363. doi: 10.1016/j.biopha.2024.117363
  3. Takegawa N, Yonesaka K. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. Clin Colorectal Cancer. 2017;16:247-251. doi: 10.1016/j.clcc.2017.03.001
  4. Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. Int J Mol Sci. 2021;22(13):6813. doi: 10.3390/ijms22136813
  5. Yoshikawa A, Nakamura Y. Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer. Cancers. 2022;15(1):183. doi: 10.3390/cancers15010183
  6. Jin M, Frankel WL. Lymph Node Metastasis in Colorectal Cancer. Surg Oncol Clin N Am. 2018;27(2):401-412. doi: 10.1016/j.soc.2017.11.011
  7. Lee DH, Lee JM. Whole-body PET/MRI for colorectal cancer staging: Is it the way forward? J Magn Reson Imaging. 2017;45(1):21-35. doi: 10.1002/jmri.25337
  8. Fraum TJ, Owen JW, Fowler KJ. Beyond Histologic Staging: Emerging Imaging Strategies in Colorectal Cancer with Special Focus on Magnetic Resonance Imaging. Clin Colon Rectal Surg. 2016;29(3):205-215. doi: 10.1055/s-0036-1584288
  9. Shen G, Hu S, Liu B, Kuang A. Diagnostic Performance of Whole-Body PET/MRI for Detecting Malignancies in Cancer Patients: A Meta-Analysis. PLoS ONE. 2016;11(4):e0154497. doi: 10.1371/journal.pone.0154497
  10. Guglielmo P, Marturano F, Bettinelli A, Gregianin M, Paiusco M, Evangelista L. Additional Value of PET Radiomic Features for the Initial Staging of Prostate Cancer: A Systematic Review from the Literature. Cancers. 2021;13(23):6026. doi: 10.3390/cancers13236026
  11. Vuong D, Tanadini-Lang S, Huellner MW, et al. Interchangeability of radiomic features between [18F]-FDG PET/CT and [18F]-FDG PET/MR. Med Phys. 2019;46(4):1677-1685. doi: 10.1002/mp.13422
  12. Palumbo B, Bianconi F, Palumbo I, et al. Value of Shape and Texture Features from 18F-FDG PET/CT to Discriminate between Benign and Malignant Solitary Pulmonary Nodules: An Experimental Evaluation. Diagnostics. 2020;10(9):696. doi: 10.3390/diagnostics10090696
  13. Zhao Q, Shi C-Z, Luo L-P. Role of the texture features of images in the diagnosis of solitary pulmonary nodules in different sizes. Chin J Cancer Res. 2014;26:451-458. doi: 10.3978/j.issn.1000-9604.2014.08.07
  14. Vallières M, Freeman CR, Skamene SR, El Naqa I. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol. 2015;60(4):5471-5496. doi: 10.1088/0031-9155/60/14/5471
  15. Mirshahvalad SA, Hinzpeter R, Kohan A, et al. Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022;49(12):4205-4217. doi: 10.1007/s00259-022-05871-0
  16. Feng L, Liu Z, Li C, et al. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. Lancet Digit Health. 2022;4(1):e8-e17. doi: 10.1016/S2589-7500(21)00215-6
  17. Xue T, Peng H, Chen Q, Li M, Duan S, Feng F. Preoperative prediction of KRAS mutation status in colorectal cancer using a CT-based radiomics nomogram. Br J Radiol. 2022;95(1134):20211014. doi: 10.1259/bjr.20211014
  18. Xue T, Peng H, Chen Q, Li M, Duan S, Feng F. Preoperative Prediction of BRAF Mutation Status in Colorectal Cancer Using a Clinical-radiomics Model. Acad Radiol. 2022;29(9):1298-1307. doi: 10.1016/j.acra.2021.12.016
  19. Golia Pernicka JS, Gagniere J, Chakraborty J, et al. Radiomics-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation. Abdom Radiol (NY). 2019;44(11):3755-3763. doi: 10.1007/s00261-019-02117-w
  20. Wang H, Chen X, Ding J, et al. Novel multiparametric MRI-based radiomics in preoperative prediction of perirectal fat invasion in rectal cancer. Abdom Radiol (NY). 2023;48(2):471-485. doi: 10.1007/s00261-022-03759-z
  21. Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28(11):1481-1491. doi: 10.1038/modpathol.2015.98
  22. Oliva MR, Saini S. Liver cancer imaging: role of CT, MRI, US and PET. Cancer Imaging. 2004;4(suppl A):S42-S46. doi: 10.1102/1470-7330.2004.0011
  23. Nioche C, Orlhac F, Boughdad S, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018;78(16):4786-4789. doi: 10.1158/0008-5472.CAN-18-0125
  24. Zhang Y, Zhou X, Li P, Li C, Ke L. XGBoost-based model for predicting five-year survival in gastric cancer using clinical indicators. Sci Rep. 2026;16(1). doi: 10.1038/s41598-026-50043-x
  25. Li T, Qi W, Mao X, et al. Prediction of lumbar disc degeneration based on interpretable machine learning models: retrospective cohort study. Spine J. 2025;25(10):2335-2348. doi: 10.1016/j.spinee.2025.04.004
  26. Seto H, Oyama A, Kitora S, et al. Gradient boosting decision tree becomes more reliable than logistic regression in predicting probability for diabetes with big data. Sci Rep. 2022;12(1):15889. doi: 10.1038/s41598-022-20149-z
  27. Srisuradetchai P, Suksrikran K. Random kernel k-nearest neighbors regression. Front Big Data. 2024;7:1402384. doi: 10.3389/fdata.2024.1402384
  28. Narayanan H, Sokolov M, Butté A, Morbidelli M. Decision Tree-PLS (DT-PLS) algorithm for the development of process: Specific local prediction models. Biotechnol Prog. 2019;35(4). doi: 10.1002/btpr.2818
  29. Luo X, Wen X, Zhou M, Abusorrah A, Huang L. Decision-Tree-Initialized Dendritic Neuron Model for Fast and Accurate Data Classification. IEEE Trans Neural Netw Learn Syst. 2022;33(9):4173-4183. doi: 10.1109/TNNLS.2021.3055991
  30. Lubiński J, Lener MR, Marciniak W, et al. Serum Essential Elements and Survival after Cancer Diagnosis. Nutrients. 2023;15(11):2611. doi: 10.3390/nu15112611
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing